Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03368807 · ClinicalTrials.gov registry record
Assessment of Mealtime Bolus Insulin Behavior
A clinical trial of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- 79
- Enrollment target
- 6
- Study locations
NCT03368807 is a study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1 that has completed, run by Eli Lilly and Company. The registered enrollment target is 79 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT03368807, a study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- 79 participants
- Enrollment target
- 6
- Study locations
Study Summary
The main purpose of this study is to estimate missed bolus insulin doses in diabetics. This is a 12-week, single-arm, outpatient, exploratory study with two study periods in Type 1 or Type 2 diabetics, with an investigational reusable injection pen, insulin, and a Continuous Glucose Monitoring (CGM) device.
Conditions Studied
Interventions
- DEVICE Continuous Glucose Monitoring
- DRUG Insulin Lispro
Study Locations (6)
California
- AMCR Institute, Inc. - Escondido
- Science 37 Inc - Los Angeles
- Coastal Metabolic Research Ctr - Ventura
Idaho
- Rocky Mountain Diabetes and Osteoporosis Center - Idaho Falls
Iowa
- Iowa Diabetes & Endocrinology Research Center - West Des Moines
Utah
- Advanced Research Institute - Ogden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2017-12-11 |
| Est. Completion | 2018-07-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03368807
The ClinicalTrials.gov registry entry for NCT03368807 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Continuous Glucose Monitoring is the first listed.
NCT03368807 reports 6 study locations spanning 4 distinct geographic areas - top geographies include California, Idaho, Iowa.
Frequently Asked Questions
What is clinical trial NCT03368807 about?
NCT03368807 is a clinical study titled "Assessment of Mealtime Bolus Insulin Behavior". The main purpose of this study is to estimate missed bolus insulin doses in diabetics. This is a 12-week, single-arm, outpatient, exploratory study with two study periods in Type 1 or Type 2 diabetics, with an investigational reusable injection pen, insulin, and a Continuous Glucose Monitoring (CGM)...
What is the current status of trial NCT03368807?
This trial is currently completed. The enrollment target is 79 participants. The study started on 2017-12-11. Estimated completion is 2018-07-23.
What conditions does trial NCT03368807 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT03368807?
The interventions under investigation include: Continuous Glucose Monitoring (DEVICE), Insulin Lispro (DRUG).
Who is sponsoring clinical trial NCT03368807?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03368807 being conducted?
This trial has 6 study locations across California, Idaho, Iowa, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Drug Interaction Potential of Pro-Inflammatory Conditions
RECRUITING
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
RECRUITING · Phase 1
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.